Aditx Therapeutics (ADTX)
(Real Time Quote from BATS)
$0.43 USD
-0.02 (-3.59%)
Updated Sep 19, 2024 09:34 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADTX 0.43 -0.02(-3.59%)
Will ADTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADTX
Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
ADTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Other News for ADTX
Aditxt and Evofem amend merger agreement
Aditxt files to sell $150M of common stock for holders
Aditxt files to sell $150M of common stock
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic? Prostate Test, Targeting Early Detection in High-Risk Patients
Aditxt?s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic? Endometriosis Test (MET?) and Mitomic? Prostate Test (MPT?)